Research programme: antisense drug therapies - Amgen/Isis

Drug Profile

Research programme: antisense drug therapies - Amgen/Isis

Alternative Names: Antisense drug therapies research programme - Amgen/Isis; Antisense oligonucleotides research programme - Amgen/Isis; Research programme: antisense oligonucleotides - Amgen/Isis

Latest Information Update: 27 Jul 2005

Price : $50

At a glance

  • Originator Amgen; Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2004 Discontinued - Preclinical for Undefined in USA (unspecified route)
  • 17 Dec 2001 New profile
  • 17 Dec 2001 Preclinical development for Undefined in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top